Abstract
Objective: To evaluate the clinical efficacy of intravenous recombinant human brain natriuretic peptide (rhBNP) in patients with acute myocardial infarction after on-pump coronary artery bypass grafting (CABG). Methods: 40 cases of coronary heart disease, left ventricular ejection fraction < 50% and? plasma brain natriuretic peptide in type N terminal? NT-proBNP > 300 pg/ml underwent on-pump coronary artery bypass surgery with cardiopulmonary bypass were enrolled and randomly divided into two groups, experimental group of 20 patients after operation on the basis of conventional therapy plus recombinant human brain natriuretic peptide treatment (first loading dose of 1.5 ?g/kg intravenously, to maintain dose of 0.01 ?g/kg/min continuous infusion of 72h), 20 cases of the control group was given routine treatment, observe two groups of patients before and after treatment of blood pressure, heart rate, urine volume, blood creatinine and NT-proBNP, and to observe the left ventricular ejection fraction (LVEF), echocardiography and the length of time the index. Results: the experimental group after treatment, urine volume, left ventricular ejection fraction (LVEF), cardiac index (CI) was significantly higher than that before treatment, the serum creatinine, plasma N - terminal pro brain natriuretic peptide (NT-proBNP), the content of serum troponin T peptide (cT nT), creatine kinase isoenzyme (CK MB) was significantly lower than before treatment. Conclusion: Recombinant human brain natriuretic peptide can improve cardiac and renal function in patients with acute period of acute myocardial infarction underwent coronary artery bypass surgery, shorten the hospitalization time, and it is safe and feasible.